Common insecticides have been linked in studies to neurodevelopmental disorders.

Published Date: 26 Apr 2023

According to a recent study from The University of Toledo, even at levels that are currently recognized, early exposure to the common class of insecticides known as pyrethroids may increase the risk of autism and other developmental disorders.

Read Full News

Latest News

Satralizumab Demonstrates Long-term Efficacy and Safety in Patients With NMOSD Louie Pasculli

A recent study confirms satralizumab's long-term safety and efficacy for treating neuromyelitis optica spectrum disorder, supporting its use as a maintenance therapy.

Case Report Suggests Progressive Brain Atrophy May Occur in NMOSD Without Relapse Marco Meglio

A case report reveals cognitive decline and brain atrophy in a patient with NMOSD, highlighting potential subclinical neurodegeneration despite limited relapses.

NeurologyLive® Friday 5 — November 21, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 21, 2025.

First Patient Dosed in Phase 2 Extension Study of Sabirnetug in Early Alzheimer Disease Louie Pasculli

Acumen Pharmaceuticals initiates a phase 2 trial extension for sabirnetug, targeting early Alzheimer disease and aiming for long-term safety insights.

NeurologyLive® Brain Games: November 23, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neural network plasticity after stroke!

Multi-Arm Phase 2 Trial Fails to Show Efficacy for Cognitive Programs in Treating Long COVID Marco Meglio

A recent trial reveals that online cognitive training and other interventions are ineffective for treating long COVID cognitive symptoms, highlighting treatment challenges.

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Latest News

A recent study confirms satralizumab's long-term safety and efficacy for treating neuromyelitis optica spectrum disorder, supporting its use as a maintenance therapy.

A case report reveals cognitive decline and brain atrophy in a patient with NMOSD, highlighting potential subclinical neurodegeneration despite limited relapses.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 21, 2025.

Acumen Pharmaceuticals initiates a phase 2 trial extension for sabirnetug, targeting early Alzheimer disease and aiming for long-term safety insights.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neural network plasticity after stroke!

A recent trial reveals that online cognitive training and other interventions are ineffective for treating long COVID cognitive symptoms, highlighting treatment challenges.

News All Time

NeurologyLive® Brain Games: November 16, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on CAR-T therapy for autoimmune neurologic diseases!

This Week on NeurologyLive® — November 17, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Multidisciplinary Care Paths That Improve Neurosarcoidosis Management Spencer Hutto, MD, Marco Meglio

Spencer Hutto, MD, associate program director of the adult neurology residency at Emory University, outlined the key diagnostic nuances, treatment considerations, and emerging therapeutic strategies shaping modern neurosarcoidosis care.

Clene to Submit Application for CNM-Au8 as Potential ALS Treatment Marco Meglio

Clene Nanomedicine prepares to submit an NDA for CNM-Au8, a promising ALS treatment, aiming for accelerated FDA approval by 2026.

Decoding the Circuitry That Stabilizes Memory Maps in the Hippocampus Marco Meglio

Jayeeta Basu, PhD, an assistant professor in the departments of Psychiatry and Neuroscience at NYU Langone, commented on how newly decoded entorhinal–hippocampal circuits stabilize memory maps during learning.

Nerivio REN Wearable Delivers Consistent Drug-Free Relief Over 3 Years, Study Shows Louie Pasculli

A new study confirms the Nerivio REN wearable provides long-term, drug-free migraine relief without dosage increases, ensuring consistent effectiveness over 3 years.

Targeting Myasthenia Gravis at the Source: Promising Progress of CAR-T Agent KYV-101 Marco Meglio

Naji Gehchan, MD, MSc, chief medical and development officer Kyverna, discussed how KYV-101 may redefine generalized myasthenia gravis care through deep B-cell depletion and durable, drug-free remission.

Study Forecasts Uptick in ALS Prevalence in Coming Decades Isabella Ciccone, MPH

Results of a new study funded by the ALS Association showed that the global prevalence of patients living with amyotrophic lateral sclerosis may increase by 25% by 2040.

Exploring the Growth and Challenges of Genetic Counseling Louie Pasculli, Carrie Haverty, MS, CGC

Carrie Haverty, MS, CGC, NSGC president-elect, discusses the evolving role of genetic counselors, emphasizing personalized care, gene therapy advancements, and the need for multidisciplinary integration in health care.

NeuroVoices: Tanya Simuni, MD, FAAN, on Emerging Directions in Disease-Modifying Therapy Trials for Parkinson Disease Tanya Simuni, MD, FAAN, Isabella Ciccone, MPH

At MDS 2025, the professor of neurology at Northwestern University Feinberg School of Medicine discussed the evolving landscape of disease-modifying clinical trials in Parkinson disease.

Gene 'switch' reverses Alzheimer's risk in experimental model

University of Kentucky researchers have developed a new experimental model that could point the way toward more effective Alzheimer's disease treatments by targeting one of the brain's most important genes for risk and resilience.

Parents of neurodivergent kids need support. But those who need it most often wait longer

Parenting any young child is full of highs and lows. In addition to these, parents and caregivers of children with neurodevelopmental conditions such as autism and attention-deficit hyperactivity disorder (ADHD) are more ...

Study shows over 90% of older adults with dementia undergo burdensome interventions in their final year

A new study by researchers from Duke-NUS Medical School has revealed that almost all community-dwelling older adults with advanced dementia in Singapore experience at least one potentially burdensome intervention in their ...

Mild cognitive impairment, dementia risk up with increasing biological severity of Alzheimer's disease

For individuals who are currently cognitively unimpaired, the lifetime and 10-year absolute risk of mild cognitive impairment (MCI) and dementia increases with increasing amyloid positron emission tomography (PET) centiloid ...

What polymers can teach us about curing Alzheimer's disease

Researchers from Tokyo Metropolitan University have applied ideas from polymer physics to illuminate the mechanism behind a key pathology in Alzheimer's disease, the formation of fibrils of tau proteins. They showed that ...

Next-generation microbiome medicine may transform Parkinson's treatment

The age-old advice to "trust your gut" could soon take on new meaning for people diagnosed with Parkinson's disease, thanks to a creative feat of bioengineering by researchers in the University of Georgia's College of Veterinary ...

Recommended News For You

Should the UK introduce targeted prostate cancer screening? The case for and against

The discovery of drug combinations may increase the life expectancy of children with brain cancer.

Researchers discover cellular 'doorway' exploited by cancer-causing virus

La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.

Routine breast cancer screening can bring better outcomes for patients

A retrospective study examined the role of CA 19-9 and CEA in duodenal adenocarcinoma prognosis.

Drop in credit score after cancer diagnosis linked to increased mortality

Recommended Articles For You

Vaccines that can help prevent cancer 

A New Perspective on Spherocytosis: Uncovering Innovative Treatments 

Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care 

Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Survey shows cancer anxiety has impact well beyond the individual diagnosed

2.

Cancer care crowdfunding increasingly common, but rarely successful

3.

Novel radiotracer identifies biomarker for triple-negative breast cancer

4.

Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

5.

June 20, 2023, Health Bulletin No. 12.

1.

Radioligand Therapy Advances: PSMA, Neuroendocrine, and Solid Tumor Clinical Insights

2.

Navigating the Complexities of Melanoma Staging: A Comprehensive Guide

3.

Navigating the Stages of Thyroid Cancer: A Guide for Patients

4.

Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology

5.

Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

2.

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients

3.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

4.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

5.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot